Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 11/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15413640 | 0.75 | FGFR4 (0.40) | FGFR4FGFR1 | |
| SCHEMBL23653249 | 0.74 | FGFR4 (0.43) | FGFR4FGFR1 | |
| SCHEMBL15434002 | 0.71 | FGFR4 (0.49) | FGFR4FGFR1SRC | |
| SCHEMBL15611171 | 0.70 | FGFR4 (0.59) | FGFR4 | |
| SCHEMBL15434004 | 0.67 | FGFR4 (0.62) | FGFR4 | |
| SCHEMBL20706002 | 0.64 | FGFR4 (0.42) | FGFR4FGFR1 | |
| SCHEMBL24225223 | 0.61 | FGFR4 (0.49) | FGFR4MAP4K1FGFR1 | |
| SCHEMBL15434048 | 0.60 | FGFR1 (0.73) | FGFR4FGFR1 | |
| SCHEMBL21386689 | 0.59 | CD44 (0.41) | SRC | |
| SCHEMBL15434045 | 0.59 | FGFR1 (0.67) | FGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872491-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | Blueprint Medicines Corporation (US) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |